M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
NCT00477906
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
387
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
Interventions
BIOLOGICAL:
M-Vax- autologous, hapten-modified melanoma vaccine
Sponsor
AVAX Technologies